Haroon Shaikh, PhD1*, Cindy Flamann, PhD2,3*, Carina Matos, PhD4*, Hla Ali, MSc5*, Michael AG Kern1*, Marina Kreutz, PhD4*, Maike Buettner-Herold6*, Christopher Lischer, MSc2*, Simon Voelkl, PhD7,8,9,10*, Christian Kellner, PhD11*, Katrin Bitterer, MTA2*, Domenica Saul, MTA2*, Ernst Holler, MD, PhD12*, Alma Zernecke, MD5*, Dimitrios Mougiakakos, MD13, Andreas Beilhack14* and Heiko Bruns, PhD8,9,15*
1Department of Medicine II, University Hospital Würzburg, Würzburg, Germany
2Department of Internal Medicine 5 – Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany
3University Hospital Erlangen, Erlangen, DEU
4Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany
5Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany
6Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany
7Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany
8Bavarian Cancer Research Center (BZKF), Erlangen, Germany
9Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
10Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany
11Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital, LMU Munich, Munich, Germany
12Internal Medicine III - Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
13Department of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany
14Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
15Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen, Erlangen, Bavaria, Germany